Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 9Neoplasm Metastasis 2Adenocarcinoma of Lung 2Thrombocytopenia 1Smoking 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neutropenia 1Mesothelioma 1Cytopenia 1Anemia 1

Interventions

Tomography, X-Ray Computed 2Tobacco Use Cessation Devices 2Vitamin B 12 1Videotape Recording 1Varenicline 1Standard of Care 1Smoking Devices 1Radon 1Psychiatric Rehabilitation 1Practice Guidelines as Topic 1Phlebotomy 1Patient Navigation 1Nicotine 1Mass Screening 1Folic Acid 1Focus Groups 1Erlotinib Hydrochloride 1Cycloserine 1Bupropion 1Budesonide 1Bronchoscopy 1Blood Specimen Collection 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoking × Folic Acid × Thoracic × Clear all
NCT00606502 2021-03-05

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

Spectrum Pharmaceuticals, Inc

Phase 2 Completed
201 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Smoking

Data powered by HemOnc (CC BY 4.0) Colophon âš¡